nodes	percent_of_prediction	percent_of_DWPC	metapath
Dinoprostone—SLCO3A1—Methotrexate—lymphatic system cancer	0.17	0.194	CbGbCtD
Dinoprostone—SLC22A2—Cytarabine—lymphatic system cancer	0.132	0.151	CbGbCtD
Dinoprostone—SLC22A1—Cytarabine—lymphatic system cancer	0.115	0.132	CbGbCtD
Dinoprostone—SLCO1C1—Methotrexate—lymphatic system cancer	0.108	0.124	CbGbCtD
Dinoprostone—CYP1A2—Carmustine—lymphatic system cancer	0.059	0.0675	CbGbCtD
Dinoprostone—SLC22A11—Methotrexate—lymphatic system cancer	0.056	0.0641	CbGbCtD
Dinoprostone—SLC22A7—Methotrexate—lymphatic system cancer	0.0533	0.061	CbGbCtD
Dinoprostone—ABCC4—Methotrexate—lymphatic system cancer	0.0521	0.0596	CbGbCtD
Dinoprostone—SLCO1A2—Methotrexate—lymphatic system cancer	0.0374	0.0428	CbGbCtD
Dinoprostone—SLCO1B1—Methotrexate—lymphatic system cancer	0.0353	0.0404	CbGbCtD
Dinoprostone—SLC22A8—Methotrexate—lymphatic system cancer	0.0326	0.0373	CbGbCtD
Dinoprostone—SLC22A6—Methotrexate—lymphatic system cancer	0.0227	0.026	CbGbCtD
Dinoprostone—Endometritis—Mitoxantrone—lymphatic system cancer	0.0169	0.134	CcSEcCtD
Dinoprostone—Hearing impaired—Fludarabine—lymphatic system cancer	0.00215	0.017	CcSEcCtD
Dinoprostone—Deafness—Fludarabine—lymphatic system cancer	0.00166	0.0132	CcSEcCtD
Dinoprostone—Wheezing—Bleomycin—lymphatic system cancer	0.00146	0.0116	CcSEcCtD
Dinoprostone—Bronchospasm—Teniposide—lymphatic system cancer	0.00144	0.0114	CcSEcCtD
Dinoprostone—Dehydration—Fludarabine—lymphatic system cancer	0.00138	0.011	CcSEcCtD
Dinoprostone—Neck stiffness—Methotrexate—lymphatic system cancer	0.00128	0.0101	CcSEcCtD
Dinoprostone—Sweating increased—Fludarabine—lymphatic system cancer	0.00125	0.00992	CcSEcCtD
Dinoprostone—Nuchal rigidity—Methotrexate—lymphatic system cancer	0.00117	0.00927	CcSEcCtD
Dinoprostone—Acute coronary syndrome—Fludarabine—lymphatic system cancer	0.00113	0.00895	CcSEcCtD
Dinoprostone—Anaphylactic shock—Mechlorethamine—lymphatic system cancer	0.00113	0.00894	CcSEcCtD
Dinoprostone—Myocardial infarction—Fludarabine—lymphatic system cancer	0.00112	0.0089	CcSEcCtD
Dinoprostone—Flushing—Teniposide—lymphatic system cancer	0.00109	0.0086	CcSEcCtD
Dinoprostone—Eye pain—Carmustine—lymphatic system cancer	0.00105	0.00835	CcSEcCtD
Dinoprostone—Chills—Teniposide—lymphatic system cancer	0.00105	0.00832	CcSEcCtD
Dinoprostone—Arrhythmia—Teniposide—lymphatic system cancer	0.00105	0.00828	CcSEcCtD
Dinoprostone—Pharyngitis—Fludarabine—lymphatic system cancer	0.00102	0.00809	CcSEcCtD
Dinoprostone—Deafness—Vincristine—lymphatic system cancer	0.00102	0.00804	CcSEcCtD
Dinoprostone—Bronchospasm—Bleomycin—lymphatic system cancer	0.000927	0.00734	CcSEcCtD
Dinoprostone—Chills—Fludarabine—lymphatic system cancer	0.000923	0.00731	CcSEcCtD
Dinoprostone—Arrhythmia—Fludarabine—lymphatic system cancer	0.000919	0.00728	CcSEcCtD
Dinoprostone—Anaphylactoid reaction—Mitoxantrone—lymphatic system cancer	0.000914	0.00724	CcSEcCtD
Dinoprostone—Hypertension—Teniposide—lymphatic system cancer	0.000879	0.00697	CcSEcCtD
Dinoprostone—Chest pain—Teniposide—lymphatic system cancer	0.000867	0.00687	CcSEcCtD
Dinoprostone—Cardiac arrest—Vincristine—lymphatic system cancer	0.000864	0.00684	CcSEcCtD
Dinoprostone—Urinary retention—Vincristine—lymphatic system cancer	0.000864	0.00684	CcSEcCtD
Dinoprostone—Dehydration—Vincristine—lymphatic system cancer	0.000845	0.00669	CcSEcCtD
Dinoprostone—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.000831	0.00658	CcSEcCtD
Dinoprostone—Acute coronary syndrome—Bleomycin—lymphatic system cancer	0.000828	0.00656	CcSEcCtD
Dinoprostone—Myocardial infarction—Bleomycin—lymphatic system cancer	0.000823	0.00652	CcSEcCtD
Dinoprostone—Dehydration—Mitoxantrone—lymphatic system cancer	0.000823	0.00652	CcSEcCtD
Dinoprostone—Tachycardia—Teniposide—lymphatic system cancer	0.000811	0.00643	CcSEcCtD
Dinoprostone—Hyperhidrosis—Teniposide—lymphatic system cancer	0.000804	0.00637	CcSEcCtD
Dinoprostone—Cough—Fludarabine—lymphatic system cancer	0.000781	0.00619	CcSEcCtD
Dinoprostone—Hypotension—Teniposide—lymphatic system cancer	0.000777	0.00616	CcSEcCtD
Dinoprostone—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.000772	0.00611	CcSEcCtD
Dinoprostone—Arthralgia—Fludarabine—lymphatic system cancer	0.000762	0.00604	CcSEcCtD
Dinoprostone—Myalgia—Fludarabine—lymphatic system cancer	0.000762	0.00604	CcSEcCtD
Dinoprostone—Sweating increased—Mitoxantrone—lymphatic system cancer	0.000745	0.0059	CcSEcCtD
Dinoprostone—Dyspnoea—Teniposide—lymphatic system cancer	0.000741	0.00587	CcSEcCtD
Dinoprostone—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.000731	0.00579	CcSEcCtD
Dinoprostone—Vomiting—Mechlorethamine—lymphatic system cancer	0.000717	0.00568	CcSEcCtD
Dinoprostone—Rash—Mechlorethamine—lymphatic system cancer	0.000711	0.00563	CcSEcCtD
Dinoprostone—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00071	0.00563	CcSEcCtD
Dinoprostone—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.000706	0.0056	CcSEcCtD
Dinoprostone—Flushing—Bleomycin—lymphatic system cancer	0.0007	0.00554	CcSEcCtD
Dinoprostone—Acute coronary syndrome—Vincristine—lymphatic system cancer	0.00069	0.00547	CcSEcCtD
Dinoprostone—Myocardial infarction—Vincristine—lymphatic system cancer	0.000686	0.00544	CcSEcCtD
Dinoprostone—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00068	0.00539	CcSEcCtD
Dinoprostone—Musculoskeletal stiffness—Methotrexate—lymphatic system cancer	0.000677	0.00536	CcSEcCtD
Dinoprostone—Chills—Bleomycin—lymphatic system cancer	0.000677	0.00536	CcSEcCtD
Dinoprostone—Skin discolouration—Methotrexate—lymphatic system cancer	0.000672	0.00533	CcSEcCtD
Dinoprostone—Acute coronary syndrome—Mitoxantrone—lymphatic system cancer	0.000672	0.00532	CcSEcCtD
Dinoprostone—Nausea—Mechlorethamine—lymphatic system cancer	0.00067	0.00531	CcSEcCtD
Dinoprostone—Myocardial infarction—Mitoxantrone—lymphatic system cancer	0.000668	0.00529	CcSEcCtD
Dinoprostone—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.000666	0.00527	CcSEcCtD
Dinoprostone—Abdominal pain—Teniposide—lymphatic system cancer	0.000657	0.00521	CcSEcCtD
Dinoprostone—Body temperature increased—Teniposide—lymphatic system cancer	0.000657	0.00521	CcSEcCtD
Dinoprostone—Paraesthesia—Fludarabine—lymphatic system cancer	0.000656	0.0052	CcSEcCtD
Dinoprostone—Dyspnoea—Fludarabine—lymphatic system cancer	0.000651	0.00516	CcSEcCtD
Dinoprostone—Inflammation—Methotrexate—lymphatic system cancer	0.000626	0.00496	CcSEcCtD
Dinoprostone—Pain—Fludarabine—lymphatic system cancer	0.000625	0.00495	CcSEcCtD
Dinoprostone—Hypersensitivity—Teniposide—lymphatic system cancer	0.000612	0.00485	CcSEcCtD
Dinoprostone—Flushing—Carmustine—lymphatic system cancer	0.000611	0.00484	CcSEcCtD
Dinoprostone—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.000607	0.00481	CcSEcCtD
Dinoprostone—Vaginal inflammation—Methotrexate—lymphatic system cancer	0.000607	0.00481	CcSEcCtD
Dinoprostone—Asthenia—Teniposide—lymphatic system cancer	0.000596	0.00473	CcSEcCtD
Dinoprostone—Arrhythmia—Carmustine—lymphatic system cancer	0.000588	0.00466	CcSEcCtD
Dinoprostone—Body temperature increased—Fludarabine—lymphatic system cancer	0.000578	0.00458	CcSEcCtD
Dinoprostone—Vaginal infection—Methotrexate—lymphatic system cancer	0.000573	0.00454	CcSEcCtD
Dinoprostone—Cough—Bleomycin—lymphatic system cancer	0.000573	0.00454	CcSEcCtD
Dinoprostone—Angiopathy—Vincristine—lymphatic system cancer	0.00057	0.00452	CcSEcCtD
Dinoprostone—Diarrhoea—Teniposide—lymphatic system cancer	0.000569	0.00451	CcSEcCtD
Dinoprostone—Chest pain—Bleomycin—lymphatic system cancer	0.000559	0.00443	CcSEcCtD
Dinoprostone—Myalgia—Bleomycin—lymphatic system cancer	0.000559	0.00443	CcSEcCtD
Dinoprostone—Back pain—Carmustine—lymphatic system cancer	0.000554	0.00439	CcSEcCtD
Dinoprostone—Chills—Mitoxantrone—lymphatic system cancer	0.000549	0.00435	CcSEcCtD
Dinoprostone—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.000547	0.00433	CcSEcCtD
Dinoprostone—Vision blurred—Carmustine—lymphatic system cancer	0.00054	0.00428	CcSEcCtD
Dinoprostone—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000538	0.00427	CcSEcCtD
Dinoprostone—Tremor—Carmustine—lymphatic system cancer	0.000537	0.00425	CcSEcCtD
Dinoprostone—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.000536	0.00424	CcSEcCtD
Dinoprostone—Back pain—Vincristine—lymphatic system cancer	0.000529	0.00419	CcSEcCtD
Dinoprostone—Vomiting—Teniposide—lymphatic system cancer	0.000529	0.00419	CcSEcCtD
Dinoprostone—Asthenia—Fludarabine—lymphatic system cancer	0.000524	0.00415	CcSEcCtD
Dinoprostone—Rash—Teniposide—lymphatic system cancer	0.000524	0.00415	CcSEcCtD
Dinoprostone—Dermatitis—Teniposide—lymphatic system cancer	0.000524	0.00415	CcSEcCtD
Dinoprostone—Headache—Teniposide—lymphatic system cancer	0.000521	0.00413	CcSEcCtD
Dinoprostone—Back pain—Mitoxantrone—lymphatic system cancer	0.000515	0.00408	CcSEcCtD
Dinoprostone—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000502	0.00398	CcSEcCtD
Dinoprostone—Hypotension—Bleomycin—lymphatic system cancer	0.000501	0.00397	CcSEcCtD
Dinoprostone—Diarrhoea—Fludarabine—lymphatic system cancer	0.0005	0.00396	CcSEcCtD
Dinoprostone—Hypertension—Carmustine—lymphatic system cancer	0.000495	0.00392	CcSEcCtD
Dinoprostone—Nausea—Teniposide—lymphatic system cancer	0.000494	0.00391	CcSEcCtD
Dinoprostone—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000488	0.00387	CcSEcCtD
Dinoprostone—Chest pain—Carmustine—lymphatic system cancer	0.000488	0.00387	CcSEcCtD
Dinoprostone—Myalgia—Carmustine—lymphatic system cancer	0.000488	0.00387	CcSEcCtD
Dinoprostone—Paraesthesia—Bleomycin—lymphatic system cancer	0.000481	0.00381	CcSEcCtD
Dinoprostone—Dyspnoea—Bleomycin—lymphatic system cancer	0.000478	0.00378	CcSEcCtD
Dinoprostone—Hypertension—Vincristine—lymphatic system cancer	0.000472	0.00374	CcSEcCtD
Dinoprostone—Myalgia—Vincristine—lymphatic system cancer	0.000466	0.00369	CcSEcCtD
Dinoprostone—Cough—Mitoxantrone—lymphatic system cancer	0.000465	0.00368	CcSEcCtD
Dinoprostone—Vomiting—Fludarabine—lymphatic system cancer	0.000465	0.00368	CcSEcCtD
Dinoprostone—Rash—Fludarabine—lymphatic system cancer	0.000461	0.00365	CcSEcCtD
Dinoprostone—Dermatitis—Fludarabine—lymphatic system cancer	0.00046	0.00365	CcSEcCtD
Dinoprostone—Hypertension—Mitoxantrone—lymphatic system cancer	0.00046	0.00364	CcSEcCtD
Dinoprostone—Pain—Bleomycin—lymphatic system cancer	0.000458	0.00363	CcSEcCtD
Dinoprostone—Headache—Fludarabine—lymphatic system cancer	0.000458	0.00363	CcSEcCtD
Dinoprostone—Tachycardia—Carmustine—lymphatic system cancer	0.000456	0.00362	CcSEcCtD
Dinoprostone—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.000455	0.00361	CcSEcCtD
Dinoprostone—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000453	0.00359	CcSEcCtD
Dinoprostone—Chest pain—Mitoxantrone—lymphatic system cancer	0.000453	0.00359	CcSEcCtD
Dinoprostone—Myalgia—Mitoxantrone—lymphatic system cancer	0.000453	0.00359	CcSEcCtD
Dinoprostone—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000446	0.00354	CcSEcCtD
Dinoprostone—Hypotension—Carmustine—lymphatic system cancer	0.000437	0.00346	CcSEcCtD
Dinoprostone—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000435	0.00344	CcSEcCtD
Dinoprostone—Nausea—Fludarabine—lymphatic system cancer	0.000434	0.00344	CcSEcCtD
Dinoprostone—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000432	0.00342	CcSEcCtD
Dinoprostone—Shock—Mitoxantrone—lymphatic system cancer	0.000428	0.00339	CcSEcCtD
Dinoprostone—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000426	0.00338	CcSEcCtD
Dinoprostone—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000424	0.00336	CcSEcCtD
Dinoprostone—Body temperature increased—Bleomycin—lymphatic system cancer	0.000423	0.00336	CcSEcCtD
Dinoprostone—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00042	0.00333	CcSEcCtD
Dinoprostone—Paraesthesia—Carmustine—lymphatic system cancer	0.00042	0.00333	CcSEcCtD
Dinoprostone—Hypotension—Vincristine—lymphatic system cancer	0.000417	0.00331	CcSEcCtD
Dinoprostone—Dyspnoea—Carmustine—lymphatic system cancer	0.000417	0.0033	CcSEcCtD
Dinoprostone—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000407	0.00322	CcSEcCtD
Dinoprostone—Hypotension—Mitoxantrone—lymphatic system cancer	0.000406	0.00322	CcSEcCtD
Dinoprostone—Paraesthesia—Vincristine—lymphatic system cancer	0.000401	0.00318	CcSEcCtD
Dinoprostone—Pain—Carmustine—lymphatic system cancer	0.0004	0.00317	CcSEcCtD
Dinoprostone—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000396	0.00314	CcSEcCtD
Dinoprostone—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000395	0.00313	CcSEcCtD
Dinoprostone—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00039	0.00309	CcSEcCtD
Dinoprostone—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000388	0.00307	CcSEcCtD
Dinoprostone—Asthenia—Bleomycin—lymphatic system cancer	0.000384	0.00305	CcSEcCtD
Dinoprostone—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000382	0.00303	CcSEcCtD
Dinoprostone—Pain—Vincristine—lymphatic system cancer	0.000382	0.00302	CcSEcCtD
Dinoprostone—Asthma—Methotrexate—lymphatic system cancer	0.000381	0.00302	CcSEcCtD
Dinoprostone—Pain—Mitoxantrone—lymphatic system cancer	0.000372	0.00295	CcSEcCtD
Dinoprostone—Abdominal pain—Carmustine—lymphatic system cancer	0.00037	0.00293	CcSEcCtD
Dinoprostone—Body temperature increased—Carmustine—lymphatic system cancer	0.00037	0.00293	CcSEcCtD
Dinoprostone—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000365	0.00289	CcSEcCtD
Dinoprostone—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000355	0.00282	CcSEcCtD
Dinoprostone—Abdominal pain—Vincristine—lymphatic system cancer	0.000353	0.0028	CcSEcCtD
Dinoprostone—Body temperature increased—Vincristine—lymphatic system cancer	0.000353	0.0028	CcSEcCtD
Dinoprostone—Hypersensitivity—Carmustine—lymphatic system cancer	0.000345	0.00273	CcSEcCtD
Dinoprostone—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000344	0.00272	CcSEcCtD
Dinoprostone—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000344	0.00272	CcSEcCtD
Dinoprostone—Vomiting—Bleomycin—lymphatic system cancer	0.000341	0.0027	CcSEcCtD
Dinoprostone—Rash—Bleomycin—lymphatic system cancer	0.000338	0.00268	CcSEcCtD
Dinoprostone—Dermatitis—Bleomycin—lymphatic system cancer	0.000337	0.00267	CcSEcCtD
Dinoprostone—Asthenia—Carmustine—lymphatic system cancer	0.000335	0.00266	CcSEcCtD
Dinoprostone—Hypersensitivity—Vincristine—lymphatic system cancer	0.000329	0.00261	CcSEcCtD
Dinoprostone—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00032	0.00254	CcSEcCtD
Dinoprostone—Asthenia—Vincristine—lymphatic system cancer	0.00032	0.00254	CcSEcCtD
Dinoprostone—Diarrhoea—Carmustine—lymphatic system cancer	0.00032	0.00254	CcSEcCtD
Dinoprostone—Nausea—Bleomycin—lymphatic system cancer	0.000318	0.00252	CcSEcCtD
Dinoprostone—Asthenia—Mitoxantrone—lymphatic system cancer	0.000312	0.00247	CcSEcCtD
Dinoprostone—Dizziness—Carmustine—lymphatic system cancer	0.000309	0.00245	CcSEcCtD
Dinoprostone—Diarrhoea—Vincristine—lymphatic system cancer	0.000305	0.00242	CcSEcCtD
Dinoprostone—Pharyngitis—Methotrexate—lymphatic system cancer	0.000303	0.0024	CcSEcCtD
Dinoprostone—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000297	0.00236	CcSEcCtD
Dinoprostone—Vomiting—Carmustine—lymphatic system cancer	0.000297	0.00236	CcSEcCtD
Dinoprostone—Dizziness—Vincristine—lymphatic system cancer	0.000295	0.00234	CcSEcCtD
Dinoprostone—Rash—Carmustine—lymphatic system cancer	0.000295	0.00234	CcSEcCtD
Dinoprostone—Dermatitis—Carmustine—lymphatic system cancer	0.000295	0.00233	CcSEcCtD
Dinoprostone—Headache—Carmustine—lymphatic system cancer	0.000293	0.00232	CcSEcCtD
Dinoprostone—Vomiting—Vincristine—lymphatic system cancer	0.000284	0.00225	CcSEcCtD
Dinoprostone—Rash—Vincristine—lymphatic system cancer	0.000281	0.00223	CcSEcCtD
Dinoprostone—Dermatitis—Vincristine—lymphatic system cancer	0.000281	0.00223	CcSEcCtD
Dinoprostone—Headache—Vincristine—lymphatic system cancer	0.00028	0.00222	CcSEcCtD
Dinoprostone—Nausea—Carmustine—lymphatic system cancer	0.000278	0.0022	CcSEcCtD
Dinoprostone—Angiopathy—Methotrexate—lymphatic system cancer	0.000277	0.00219	CcSEcCtD
Dinoprostone—Vomiting—Mitoxantrone—lymphatic system cancer	0.000276	0.00219	CcSEcCtD
Dinoprostone—Immune system disorder—Methotrexate—lymphatic system cancer	0.000275	0.00218	CcSEcCtD
Dinoprostone—Rash—Mitoxantrone—lymphatic system cancer	0.000274	0.00217	CcSEcCtD
Dinoprostone—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000274	0.00217	CcSEcCtD
Dinoprostone—Chills—Methotrexate—lymphatic system cancer	0.000274	0.00217	CcSEcCtD
Dinoprostone—Headache—Mitoxantrone—lymphatic system cancer	0.000272	0.00216	CcSEcCtD
Dinoprostone—Nausea—Vincristine—lymphatic system cancer	0.000265	0.0021	CcSEcCtD
Dinoprostone—Nausea—Mitoxantrone—lymphatic system cancer	0.000258	0.00205	CcSEcCtD
Dinoprostone—Back pain—Methotrexate—lymphatic system cancer	0.000257	0.00203	CcSEcCtD
Dinoprostone—Vision blurred—Methotrexate—lymphatic system cancer	0.00025	0.00198	CcSEcCtD
Dinoprostone—Cough—Methotrexate—lymphatic system cancer	0.000232	0.00183	CcSEcCtD
Dinoprostone—Arthralgia—Methotrexate—lymphatic system cancer	0.000226	0.00179	CcSEcCtD
Dinoprostone—Chest pain—Methotrexate—lymphatic system cancer	0.000226	0.00179	CcSEcCtD
Dinoprostone—Myalgia—Methotrexate—lymphatic system cancer	0.000226	0.00179	CcSEcCtD
Dinoprostone—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000217	0.00172	CcSEcCtD
Dinoprostone—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000209	0.00166	CcSEcCtD
Dinoprostone—Hypotension—Methotrexate—lymphatic system cancer	0.000202	0.0016	CcSEcCtD
Dinoprostone—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000197	0.00156	CcSEcCtD
Dinoprostone—Paraesthesia—Methotrexate—lymphatic system cancer	0.000194	0.00154	CcSEcCtD
Dinoprostone—Dyspnoea—Methotrexate—lymphatic system cancer	0.000193	0.00153	CcSEcCtD
Dinoprostone—Pain—Methotrexate—lymphatic system cancer	0.000185	0.00147	CcSEcCtD
Dinoprostone—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000177	0.0014	CcSEcCtD
Dinoprostone—Body temperature increased—Methotrexate—lymphatic system cancer	0.000171	0.00136	CcSEcCtD
Dinoprostone—Abdominal pain—Methotrexate—lymphatic system cancer	0.000171	0.00136	CcSEcCtD
Dinoprostone—Hypersensitivity—Methotrexate—lymphatic system cancer	0.00016	0.00126	CcSEcCtD
Dinoprostone—Asthenia—Methotrexate—lymphatic system cancer	0.000155	0.00123	CcSEcCtD
Dinoprostone—Diarrhoea—Methotrexate—lymphatic system cancer	0.000148	0.00117	CcSEcCtD
Dinoprostone—Dizziness—Methotrexate—lymphatic system cancer	0.000143	0.00113	CcSEcCtD
Dinoprostone—Vomiting—Methotrexate—lymphatic system cancer	0.000138	0.00109	CcSEcCtD
Dinoprostone—Rash—Methotrexate—lymphatic system cancer	0.000137	0.00108	CcSEcCtD
Dinoprostone—Dermatitis—Methotrexate—lymphatic system cancer	0.000136	0.00108	CcSEcCtD
Dinoprostone—Headache—Methotrexate—lymphatic system cancer	0.000136	0.00108	CcSEcCtD
Dinoprostone—Nausea—Methotrexate—lymphatic system cancer	0.000129	0.00102	CcSEcCtD
